Axsome Therapeutics, Inc.
AXSMDrugs in Pipeline
16
Phase 3 Programs
13
Upcoming Catalysts
6
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
6 upcoming, 0 past
Upcoming FDA decisions
How AXSM's past catalysts played out
AXS-05
Agitation in Patients With Dementia of the Alzheimer's Type
AXS-12 (reboxetine)
Narcolepsy
Solriamfetol 150 mg
Excessive Sleepiness
AXS-05 (dextromethorphan and bupropion) oral tablets
Major Depressive Disorder
Solriamfetol 300 mg
Binge-Eating Disorder
AXS-07
Migraine
AXS-07 (MoSEIC meloxicam and rizatriptan)
Migraine
AXS-07 (meloxicam-rizatriptan)
Migraine
AXS-14 (Esreboxetine)
Fibromyalgia
Bupropion
Major Depressive Disorder
AXS-05 (dextromethorphan-bupropion)
Treatment Resistant Depression
Solriamfetol Dose B
ADHD
Solriamfetol Dose A
ADHD
Dextromethorphan-Bupropion
Major Depressive Disorder (MDD)
Bupropion SR
Smoking Cessation
Solriamfetol
Multiple Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AXS-05 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type | - | - |
AXS-12 (reboxetine) | Phase 3 | Narcolepsy | - | - |
Solriamfetol 150 mg | Phase 3 | Excessive Sleepiness | - | - |
AXS-05 (dextromethorphan and bupropion) oral tablets | Phase 3 | Major Depressive Disorder | - | - |
Solriamfetol 300 mg | Phase 3 | Binge-Eating Disorder | - | - |
AXS-07 | Phase 3 | Migraine | - | - |
AXS-07 (MoSEIC meloxicam and rizatriptan) | Phase 3 | Migraine | - | - |
AXS-07 (meloxicam-rizatriptan) | Phase 3 | Migraine | - | - |
AXS-14 (Esreboxetine) | Phase 3 | Fibromyalgia | - | - |
Bupropion | Phase 3 | Major Depressive Disorder | - | - |
AXS-05 (dextromethorphan-bupropion) | Phase 3 | Treatment Resistant Depression | - | - |
Solriamfetol Dose B | Phase 3 | ADHD | - | - |
Solriamfetol Dose A | Phase 3 | ADHD | - | - |
Dextromethorphan-Bupropion | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Bupropion SR | Phase 2 | Smoking Cessation | - | - |
Solriamfetol | Phase 2 | Multiple Sclerosis | - | - |
Narcolepsy
3 drugs in this indication
Migraine
3 drugs in this indication
Major Depressive Disorder
2 drugs in this indication
Agitation in Patients With Dementia of the Alzheimer's Type
1 drug in this indication
Excessive Sleepiness
1 drug in this indication
Binge-Eating Disorder
1 drug in this indication
Treatment Resistant Depression
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Axsome Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 16 drug candidates in Axsome Therapeutics, Inc.'s (AXSM) pipeline across Phase 3, Phase 2. Its lead program is AXS-05 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Axsome Therapeutics, Inc.'s next FDA catalyst?→
Axsome Therapeutics, Inc.'s (AXSM) next tracked catalyst is a Earnings expected November 2, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AXSM biotech catalysts?→
Add AXSM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Axsome Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.